U.S. Retailers Sue AstraZeneca Over Nexium Strategy

Several subject U.S. retailers have sued AstraZeneca Plc, accusing the drugmaker of using illegal manoeuvre to maintain its control over the heartburn medicament Prilosec even after the drug’s letters patent expired in 2001.

Spot retailers, including Walgreen Co., Kroger Co. and Safeway Inc., filed a civil suit in Yankee judicature, alleging that AstraZeneca used humbug and “exclusionary conduct” to hold on to its dominant allele opinion by switching patients from Prilosec to its nearly identical, patent-protected drug Nexium.

“While this product-switching military science was enormously successful and profitable for AstraZeneca, it was an economic tragedy for Inhabitant consumers,” the lawsuit said.

AstraZeneca spokeswoman Emily Denney said late on Friday the London-based organisation “denies the claims, and we will vigorously defend against them.” She declined to elaborate.

Filed on Dec. 7 in the U.S.
District Royal court for the District of Capital of South Carolina, the lawsuit seeks base hit damages.
Exact cost figures were not specified in the suit, and a lawyer for the retailers was not immediately available for report.

The suit claimed AstraZeneca’s scheme has forced the retailers to pay artificially inflated, ascendance prices for the branded variation of the drug, known generically as omeprazole.
Nexium is also known as esomeprazole.

The lawsuit says AstraZeneca has maintained 70 percent part of the retail store and blames exclusionary manoeuvre that it says inhibited the sale of wine and over-the-counter competitors.

AstraZeneca devised a plan of action in outlook of the exhalation of the Prilosec patents, known as the Elasmobranch Fin Work, to field its socio-economic class perspective, according to the suit.

At the same time, the lawsuit claims AstraZeneca effectively withdrew Prilosec from the retail store.
The establishment got liking from the Food and Drug Giving medication to sell it over-the-counter causing some insurers to stop providing news for product Prilosec.

The costly product-switching plan of action “made no economic common sense absent its belief of impairing ware contention for Prilosec,” the lawsuit contends.
This is a part of article U.S. Retailers Sue AstraZeneca Over Nexium Strategy Taken from "Nexium Generic Esomeprazole" Information Blog